TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32145206

Group type: EXPERIMENTAL
Intervention: Low intensity pulsed ultrasound (LIPUS) stimulation (1.5 MHz, 30 mW/cm2) for 20 minutes daily on postoperative days 4, 8, 14, and 20
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low intensity pulsed ultrasound (LIPUS) stimulation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no LIPUS stimulation)
Number of subjects: 40
Study: 34387520

Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol 60,000 IU weekly for 8 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 33992263

Group type: EXPERIMENTAL
Intervention: Soft tissue techniques (mobilization, taping, and stretching) targeting lower limb range of motion (LLROM)
Number of subjects: 8
Study: 34965171

Group type: EXPERIMENTAL
Intervention: CT imaging
Number of subjects: 54

Group type: COMPARATOR
Intervention: MRI imaging
Number of subjects: 54
Study: 33941219

Group type: EXPERIMENTAL
Intervention: Hylan G‐F 20
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.9% NaCl (Control Group)
Number of subjects: 40
Study: 35108670

Group type: EXPERIMENTAL
Intervention: Ultrathin skin grafting (UTSG)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional dressing
Number of subjects: 52
Study: 34971285

Group type: EXPERIMENTAL
Intervention: Telerehabilitation group (TG) - 6-week motor-cognitive dual-task exercise training performed online under supervision.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (CG) - No physical or cognitive intervention for 6 weeks.
Number of subjects: 18
Study: 34073590

Group type: EXPERIMENTAL
Intervention: Real-time OEP phase angle and volume feedback system
Number of subjects: 18

Group type: COMPARATOR
Intervention: Real-time OEP volume feedback alone
Number of subjects: 18
Study: 32076718

Group type: EXPERIMENTAL
Intervention: Preemptive therapy
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Prophylaxis therapy
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Fifteen-day CMI risk stratification
Number of subjects: 160
Study: 616191741

Group type: EXPERIMENTAL
Intervention: Nurse Practitioner (NP) assessment
Number of subjects: 235

Group type: COMPARATOR
Intervention: Radiation Oncologist (RO) assessment
Number of subjects: 235
Study: 35128952

Group type: EXPERIMENTAL
Intervention: Well-being apps usage
Number of subjects: 0
Study: 34202464

Group type: EXPERIMENTAL
Intervention: Genomic association study using ABO-associated genetic variants as instrumental variables
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Mendelian randomization (MR) studies on blood pressures
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Mendelian randomization (MR) studies on severe COVID-19 with respiratory failure
Number of subjects: 1008
Study: 32370930

Group type: EXPERIMENTAL
Intervention: CBT + BA + CM
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Smoking Abstinence
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Reduction in Depressive Symptoms
Number of subjects: 180
Study: 35715946

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 43522

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43522

Group type: COMPARATOR
Intervention: DPP-4 inhibitors (including sitagliptin)
Number of subjects: 43522
Study: 34424530

Group type: EXPERIMENTAL
Intervention: Decitabine in alternating cycles with sapacitabine (study arm)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Decitabine monotherapy (control arm)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Decitabine in alternating cycles with sapacitabine (study arm) in patients with white blood cell counts <10 × 10^9 /L
Number of subjects: 482

Group type: COMPARATOR
Intervention: Decitabine monotherapy (control arm) in patients with white blood cell counts <10 × 10^9 /L
Number of subjects: 482
Study: 32786002

Group type: EXPERIMENTAL
Intervention: Benzodiazepine receptor agonists (BZRAs)
Number of subjects: 797

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: BZRAs
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 797
Study: 36208853

Group type: EXPERIMENTAL
Intervention: Typhoid vaccine
Number of subjects: 172

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 172
Study: 34181474

Group type: EXPERIMENTAL
Intervention: Critically drug-resistant E. coli
Number of subjects: 187619

Group type: EXPERIMENTAL
Intervention: Critically drug-resistant K. pneumoniae
Number of subjects: 187619

Group type: EXPERIMENTAL
Intervention: Critically drug-resistant Acinetobacter baumannii
Number of subjects: 187619

Group type: EXPERIMENTAL
Intervention: Critically drug-resistant Pseudomonas aeruginosa
Number of subjects: 187619

Group type: EXPERIMENTAL
Intervention: Molecular characterization of carbapenemase genes
Number of subjects: 187619
Study: 32442781

Group type: EXPERIMENTAL
Intervention: Exposure therapy (10 sessions)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Waitlist (control group)
Number of subjects: 162
Study: 35759874

Group type: EXPERIMENTAL
Intervention: Social Media Intervention + Incentives for engagement
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Social Media Intervention only
Number of subjects: 955

Group type: COMPARATOR
Intervention: Attention-placebo control
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Incentivized group
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: Non-incentivized group
Number of subjects: 955
Study: 34559054

Group type: EXPERIMENTAL
Intervention: AI-assisted health program (exercise-based, automated chatbot messages via LINE for 12 weeks)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: AI-assisted health program
Number of subjects: 94

Group type: COMPARATOR
Intervention: Usual care routines (control group)
Number of subjects: 94
Study: 36239914

Group type: EXPERIMENTAL
Intervention: Senaparib 100 mg in fasted state
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Senaparib 100 mg in fed state
Number of subjects: 16

Group type: COMPARATOR
Intervention: Safety profile in both states
Number of subjects: 16
Study: 33862206

Group type: EXPERIMENTAL
Intervention: Laparoscopic treatment (group 1), 13 patients, 2 required conversion to open surgery.
Number of subjects: 213

Group type: COMPARATOR
Intervention: Open surgery (group 2), 154 patients, 14 records compatible with laparoscopic criteria.
Number of subjects: 213
Study: 32979074

Group type: EXPERIMENTAL
Intervention: Metformin (2 g/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Metformin + Exercise Training
Number of subjects: 29

Group type: COMPARATOR
Intervention: Exercise Training Alone
Number of subjects: 29
Study: 33299545

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation delivered before major abdominal surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable (no control group mentioned)
Number of subjects: 0
Study: 36266683

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4,000 units daily for 18 weeks)
Number of subjects: 88
Study: 33684310

Group type: EXPERIMENTAL
Intervention: 600 mgI kg‐1 with 70 keV monochromatic images
Number of subjects: 40

Group type: COMPARATOR
Intervention: 300 mgI kg‐1 with 40 keV monochromatic images
Number of subjects: 40

Group type: COMPARATOR
Intervention: 300 mgI kg‐1 with 45 keV monochromatic images
Number of subjects: 40
Study: 36224307

Group type: EXPERIMENTAL
Intervention: Spatial-anxiety condition (n = 22)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control condition (n = 22)
Number of subjects: 44
Study: 34082251

Group type: EXPERIMENTAL
Intervention: 3 hours post-PEG feeding (group 1)
Number of subjects: 97

Group type: COMPARATOR
Intervention: 8 hours post-PEG feeding (group 2)
Number of subjects: 97
Study: 32825990

Group type: EXPERIMENTAL
Intervention: Osteopathic treatment (5 sessions over 8 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (8-week untreated waiting period)
Number of subjects: 70
Study: 36189565

Group type: EXPERIMENTAL
Intervention: Zinc oxide eugenol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Metapex
Number of subjects: 80
Study: 34107963

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine (ASMQ)
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: 4-day artemether-lumefantrine regimen (AL+)
Number of subjects: 511
Study: 32247539

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Number of subjects: 116

Group type: COMPARATOR
Intervention: Fentanyl boluses
Number of subjects: 116
Study: 34215149

Group type: EXPERIMENTAL
Intervention: IMPULS treatment (8 weekly sessions)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 24
Study: 35292989

Group type: EXPERIMENTAL
Intervention: Favipiravir plus interferon-beta (FVP + INF-beta)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir plus interferon-beta (LPV/RTV + INF-beta)
Number of subjects: 66
Study: 34297338

Group type: EXPERIMENTAL
Intervention: Amikacin 25 mg/kg intravenously
Number of subjects: 97

Group type: COMPARATOR
Intervention: Amikacin 15 mg/kg intravenously
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Amikacin 25 mg/kg and 15 mg/kg
Number of subjects: 97
Study: 32816094

Group type: EXPERIMENTAL
Intervention: Combined physical activity and dietary intervention
Number of subjects: 504

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 504
Study: 34810217

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus endocrine therapy (ET group, n = 196)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Trastuzumab plus chemotherapy (CT group, n = 196)
Number of subjects: 392
Study: 35675677

Group type: EXPERIMENTAL
Intervention: Mobiderm compression bandage
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional multi-layered bandages
Number of subjects: 50
Study: 34961541

Group type: EXPERIMENTAL
Intervention: Pelvis-on group (robotic gait training with pelvic movements)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pelvis-off group (robotic gait training without pelvic movements)
Number of subjects: 24
Study: 32711414

Group type: EXPERIMENTAL
Intervention: Health Systems (H)
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Health Systems and Youth intervention (HY)
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Health Systems, Community and Youth intervention (HCY)
Number of subjects: 437
Study: 36259443

Group type: EXPERIMENTAL
Intervention: Masked targets
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Faces cropped to the eyes (Study 3)
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Gaze into the eyes of faces (Study 4)
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Unmasked targets
Number of subjects: 1012
Study: 34942921

Group type: EXPERIMENTAL
Intervention: Melomics‐Health (MH) group (n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Individualized music listening (IML) group (n = 20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No music group (n = 20)
Number of subjects: 60
Study: 33085058

Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin 130 mg/m2 (SOX130)
Number of subjects: 63
Study: 34261793

Group type: EXPERIMENTAL
Intervention: VRC26.25 modified with three mutations in the CDRH3 region
Number of subjects: 0

Group type: COMPARATOR
Intervention: Original VRC26.25 antibody
Number of subjects: 0
Study: 32058608

Group type: EXPERIMENTAL
Intervention: Needleless administration of SCIT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional administration of SCIT
Number of subjects: 0
Study: 616511319

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided SWL
Number of subjects: 114

Group type: COMPARATOR
Intervention: Fluoroscopy-guided SWL
Number of subjects: 114
Study: 35021944

Group type: EXPERIMENTAL
Intervention: Nanocurcumin (80 mg/day for 8 weeks)
Number of subjects: 36
Study: 34018809

Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34526397

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 1837

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg + MTX
Number of subjects: 1837

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 1837

Group type: EXPERIMENTAL
Intervention: ADA
Number of subjects: 1837

Group type: COMPARATOR
Intervention: PBO
Number of subjects: 1837

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 1837
Study: 32139194

Group type: EXPERIMENTAL
Intervention: Medial Stabilized (MS) design
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Posterior Stabilized (PS) design
Number of subjects: 83

Group type: COMPARATOR
Intervention: Cruciate Retaining (CR) design
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Knee Society Score 2011 Satisfaction
Number of subjects: 83
Study: 33337698

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE, 1 minute 90% PPO followed by 1 minute 10% PPO, ×10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Exercise (MOD, 20 minutes at 50% PPO)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sprint-Interval Exercise (SPRT, 20 seconds 'all-out' sprints followed by 2 minutes at 50 W, ×3)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Maximal Exercise Test (MAX)
Number of subjects: 30
Study: 33308452

Group type: EXPERIMENTAL
Intervention: Organ preservation with short-course radiotherapy followed by transanal endoscopic microsurgery
Number of subjects: 55

Group type: COMPARATOR
Intervention: Total mesorectal excision
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Organ preservation
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Non-randomised organ preservation
Number of subjects: 55

Group type: COMPARATOR
Intervention: Non-randomised total mesorectal excision
Number of subjects: 55
Study: 33355713

Group type: EXPERIMENTAL
Intervention: Bicycle exercise in hypoxia (FIO2=0.15)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Bicycle exercise in normoxia (FIO2=0.21)
Number of subjects: 29
Study: 33890385

Group type: EXPERIMENTAL
Intervention: Mobile Stroke Unit (MSU)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Conventional Ambulances (Control)
Number of subjects: 440
Study: 32217612

Group type: EXPERIMENTAL
Intervention: ado-trastuzumab emtansine
Number of subjects: 0

Group type: COMPARATOR
Intervention: trastuzumab
Number of subjects: 0
Study: 34432628

Group type: EXPERIMENTAL
Intervention: Nasal dilator strips (NDS)
Number of subjects: 54
Study: 33812932

Group type: EXPERIMENTAL
Intervention: Low-frequency (1 Hz) Repetitive Transcranial Magnetic Stimulation (rTMS) at the sensory-motor integration site (Cz) for 15 minutes
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Execution task (flexing and extending the index finger)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Action observation task (watching a video of the same movement)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Motor imagery task (imagining the flexion and extension of the index finger movement)
Number of subjects: 11
Study: 32050858

Group type: EXPERIMENTAL
Intervention: Self-affirmation (affirming values that are important to the participants)
Number of subjects: 352

Group type: COMPARATOR
Intervention: No-affirmation condition
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Self-affirmation
Number of subjects: 352
Study: 33726809

Group type: EXPERIMENTAL
Intervention: Motivational network intervention (MNI) delivered by case managers
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual case manager support
Number of subjects: 60
Study: 32020032

Group type: EXPERIMENTAL
Intervention: Immediate exercise (IMX) - 6 months of supervised resistance/aerobic/impact exercise initiated at the onset of ADT
Number of subjects: 104

Group type: COMPARATOR
Intervention: Delayed exercise (DEL) - 6 months of usual care followed by 6 months of resistance/aerobic/impact exercise
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Immediate exercise (IMX)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Delayed exercise (DEL)
Number of subjects: 104
Study: 36104138

Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO) 6 mg/kg plus Ipilimumab (IPI) 1 mg/kg on day 1 of the first week of each 8-week cycle, alternating with NIVO 480 mg monotherapy on day 1 of the fifth week of each 8-week cycle
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO) 6 mg/kg plus Ipilimumab (IPI) 1 mg/kg
Number of subjects: 106
Study: 34076752

Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy (PNL)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy (SWL)
Number of subjects: 104
Study: 36154660

Group type: EXPERIMENTAL
Intervention: Direct acting antiviral treatment for hepatitis C virus (HCV)
Number of subjects: 20
Study: 33472789

Group type: EXPERIMENTAL
Intervention: Frailty+ intervention alongside standard care
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 76
Study: 36194846

Group type: EXPERIMENTAL
Intervention: Postmenopausal women (post‐MW) during postexercise muscle ischemia (PEMI)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Premenopausal women (pre‐MW) during postexercise muscle ischemia (PEMI)
Number of subjects: 31
Study: 33158777

Group type: EXPERIMENTAL
Intervention: Intraluminal brachytherapy using 125I seed strand and CT‐guided percutaneous radioactive seed implantation therapy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Chemotherapy with gemcitabine and cisplatin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Percutaneous 125I seed implantation combined with insertion of radioactive strips through the biliary stent
Number of subjects: 21
Study: 33095682

Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with trastuzumab plus lapatinib (THL)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Trastuzumab (TH)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Lapatinib (TL)
Number of subjects: 305
Study: 33580520

Group type: EXPERIMENTAL
Intervention: Cenobamate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phenobarbital
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other alkyl-carbamates
Number of subjects: 0
Study: 36475807

Group type: EXPERIMENTAL
Intervention: Scrotal Antegrade Sclerotherapy (SAS)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Laparoscopic Palomo Surgery (LPS)
Number of subjects: 113
Study: 33157269

Group type: EXPERIMENTAL
Intervention: Cannabis use after legalization (2015)
Number of subjects: 39437

Group type: COMPARATOR
Intervention: Cannabis use (any time)
Number of subjects: 39437
Study: 32591274

Group type: EXPERIMENTAL
Intervention: L-PRF membranes
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control side (no L-PRF)
Number of subjects: 17
Study: 33570225

Group type: EXPERIMENTAL
Intervention: SmartAdapt DIR tool
Number of subjects: 32
Study: 32507285

Group type: EXPERIMENTAL
Intervention: Ambu laryngeal mask airway
Number of subjects: 70

Group type: COMPARATOR
Intervention: I-gel®
Number of subjects: 70
Study: 35841075

Group type: EXPERIMENTAL
Intervention: Ethanol‐based handrub gel with superfatting agents (Saniswiss Sanitizer Hands H1)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Isopropanol‐based formulations (Hopirub® or Hopigel®)
Number of subjects: 42
Study: 33780276

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemohormonal therapy and radical prostatectomy
Number of subjects: 656

Group type: COMPARATOR
Intervention: Radical prostatectomy alone
Number of subjects: 656
Study: 32826051

Group type: EXPERIMENTAL
Intervention: Resection of LVS using various surgical techniques including speculoscopy and septum excision with electrosurgical modalities, speculoscopy with laparoscopic devices, and vaginoscopy with hysteroscopic instruments.
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Vaginoscopic incision using resectoscope.
Number of subjects: 121
Study: 36660974

Group type: EXPERIMENTAL
Intervention: High-intensity multimodal exercise training (HIT-MMEX) - supervised resistance, weight-bearing, balance and mobility training twice weekly for 8 months
Number of subjects: 28

Group type: COMPARATOR
Intervention: Low-to-moderate intensity exercises (Control group)
Number of subjects: 28
Study: 34622862

Group type: EXPERIMENTAL
Intervention: Real LF-ThMS (30-minute session, pulsed magnetic field from 100 to 118 Hz, 10.5 to 13.1 milliTesla)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham LF-ThMS
Number of subjects: 17
Study: 35405934

Group type: EXPERIMENTAL
Intervention: Jejunal Nutrition (JN) with liquid nutrient (2 kcal/min) infused for 60 min prior to a standardized meal
Number of subjects: 30

Group type: COMPARATOR
Intervention: Water (control) infused for 60 min prior to a standardized meal
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Jejunal Nutrition (JN)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Standardized mixed solid/liquid test meal
Number of subjects: 30
Study: 34461969

Group type: EXPERIMENTAL
Intervention: High PEEP ventilation strategy
Number of subjects: 3875

Group type: EXPERIMENTAL
Intervention: Fluid-conservative strategy
Number of subjects: 3875

Group type: COMPARATOR
Intervention: Phenotype I
Number of subjects: 3875

Group type: COMPARATOR
Intervention: Phenotype II
Number of subjects: 3875

Group type: COMPARATOR
Intervention: Phenotype III
Number of subjects: 3875
Study: 32616309

Group type: EXPERIMENTAL
Intervention: Sevoflurane plus i.v. lidocaine (SL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sevoflurane (S)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol plus i.v. lidocaine (PL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Propofol (P)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All anaesthetics with lidocaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: All anaesthetics without lidocaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All anaesthetics
Number of subjects: 120
Study: 36167484

Group type: COMPARATOR
Intervention: Single Vision Spectacle Lenses (SVL)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Slightly Aspherical Lenslets (SAL)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Highly Aspherical Lenslets (HAL)
Number of subjects: 170
Study: 34024502

Group type: EXPERIMENTAL
Intervention: NMES (Neuromuscular electrical stimulation) applied bilaterally at the origin and insertion points of the quadriceps or gastrocnemius muscles for 40 min during each HD session (3x/wk for one month)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 21
Study: 36419027

Group type: EXPERIMENTAL
Intervention: Birth plan group
Number of subjects: 106